173 related articles for article (PubMed ID: 2310683)
1. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
Bruning PF; Pit MJ; de Jong-Bakker M; van den Ende A; Hart A; van Enk A
Br J Cancer; 1990 Feb; 61(2):308-10. PubMed ID: 2310683
[TBL] [Abstract][Full Text] [Related]
2. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
[TBL] [Abstract][Full Text] [Related]
3. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
[TBL] [Abstract][Full Text] [Related]
5. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
McCune JS; Games DM; Espirito JL
J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
[TBL] [Abstract][Full Text] [Related]
6. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
9. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.
Oostra DR; Lustberg MB; Reinbolt RE; Pan X; Wesolowski R; Shapiro CL
Mol Cell Endocrinol; 2015 Feb; 402():51-6. PubMed ID: 25575458
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis in women with breast cancer and its effect on quality of life: a pilot study.
Turan Y; Kocaaga Z; Karakoyun-Celik O; Gurgan A; Duransoy A
J BUON; 2009; 14(2):239-43. PubMed ID: 19650173
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
Cameron DA; Douglas S; Brown JE; Anderson RA
Breast Cancer Res Treat; 2010 Oct; 123(3):805-14. PubMed ID: 20686833
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.
Monroy-Cisneros K; Esparza-Romero J; Valencia ME; Guevara-Torres AG; Méndez-Estrada RO; Anduro-Corona I; Astiazarán-García H
BMC Cancer; 2016 Nov; 16(1):860. PubMed ID: 27821086
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study.
Loo WT; Jin LJ; Cheung MN; Chow LW; Wang M
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S109-15. PubMed ID: 20374022
[TBL] [Abstract][Full Text] [Related]
14. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy.
Vehmanen LK; Elomaa I; Blomqvist CP; Saarto T
Acta Oncol; 2014 Jan; 53(1):75-9. PubMed ID: 23713891
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
19. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
Partridge A; Gelber S; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Winer E
Eur J Cancer; 2007 Jul; 43(11):1646-53. PubMed ID: 17512721
[TBL] [Abstract][Full Text] [Related]
20. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
Vehmanen L; Saarto T; Risteli J; Risteli L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2004 Sep; 87(2):181-8. PubMed ID: 15377842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
